Biogen Idec to Present at the 29th Annual J.P. Morgan Healthcare Conference

WESTON, Mass.--(BUSINESS WIRE)-- Biogen Idec Inc. (NASDAQ: BIIB) announced today that its presentation at the 29th Annual J.P. Morgan Healthcare Conference will be webcast live on Tuesday, January 11, 2011 at 3:30 p.m. PT, 6:30 p.m. ET. To access the live webcast, please visit Biogen Idec’s Investor Relations section (www.investor.biogenidec.com). An archived version of the webcast will be available for 14 days following the presentation.

About Biogen Idec

Biogen Idec uses cutting edge science to discover, develop, manufacture and market biological products for the treatment of serious diseases with a focus on neurological disorders. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates more than $4 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.



CONTACT:

Biogen Idec
Karen Jewell, 781-464-2066
Investor Relations

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.